Adcock Ingram's turnover rose 6% to R9.6bn, driven by demand for winter cold and flu medicines. HEPS grew 10%, with the final dividend rising to 275 cents.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here